What's in Azienda Ospedaliera San Gerardo di Monza's pipeline?

Azienda Ospedaliera San Gerardo di Monza has 5 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Azienda Ospedaliera San Gerardo di Monza's portfolio?

Top competitors by shared drug class: Bristol-Myers Squibb, Clinical Trial Agency of HIV Study Group, GlaxoSmithKline, Hospital Clinic of Barcelona, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/azienda-ospedaliera-san-gerardo-di-monza.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Azienda Ospedaliera San Gerardo di Monza — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azienda Ospedaliera San Gerardo di Monza pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Switch to TDF/FTC/RPV after 24 weeks	Switch to TDF/FTC/RPV after 24 weeks	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase	Infectious Disease / Virology
Immediate switch to TDF/FTC/RPV	Immediate switch to TDF/FTC/RPV	marketed	Antiretroviral combination therapy (NRTI/NNRTI)	HIV reverse transcriptase, HIV integrase	Infectious Disease / Virology
Propofol + Remifentanyl	Propofol + Remifentanyl	phase 3	Intravenous anesthetic combination (hypnotic + opioid)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil)	Anesthesiology
Sevoflurane + Remifentanyl	Sevoflurane + Remifentanyl	phase 3	General anesthetic and opioid analgesic	GABA_A receptor and opioid receptors	Anesthesiology
Sevoflurane + Fentanyl	Sevoflurane + Fentanyl	phase 3	General anesthetic + opioid analgesic combination	GABA receptors (sevoflurane); mu-opioid receptors (fentanyl)	Anesthesiology

Therapeutic area mix

Anesthesiology · 3
Infectious Disease / Virology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bristol-Myers Squibb · 1 shared drug class
Clinical Trial Agency of HIV Study Group · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Hospital Clinic of Barcelona · 1 shared drug class
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 shared drug class
National Center for AIDS/STD Control and Prevention, China CDC · 1 shared drug class
North District Hospital · 1 shared drug class
Peking Union Medical College Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azienda Ospedaliera San Gerardo di Monza:

Cite this brief

Drug Landscape (2026). Azienda Ospedaliera San Gerardo di Monza — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliera-san-gerardo-di-monza. Accessed 2026-05-17.